|
|
Diamyd Medical AB - Comparative Business Analysis Snapshot
Business Description
Diamyd Medical AB. The Group's primary activity is the development of medicine for diabetes. The Group operates in two segments: GAD technology and NTDDS technology. The GAD technology segment comprises of GAD-protein and Diamyd anti-GAD RIA-kits. The products are sold to researchers and laboratories. The NTDDS segment include the Group's first drug candidate from theNerve Targeting Drug Delivery System (NTDDS) gene therapy platform. The Group operates globally.
Competitor Analysis
This analysis compares Diamyd Medical AB with three other companies in closely related industry sectors.
The full Comparative Business Report is available to Subscribers or may be purchased individually. The full report generally includes the following sections:
- Sales Analysis: Recent Sales, Sales Growth, Sales per Employee
- Recent Stock Performance
- Company Valuation Ratios: Price/Earnings, Price/Book Value
- Price/Sales and 52 Week Price change
- Dividend Analysis
- Profitability Analysis: Gross Profit Margin, EBITDA Margin
- Earnings Before Extraordinary Items
- Inventory Analysis
- Research and Development Expenses
- Financial Position: Long Term Debt/Equity, Days Accounts Receivable, Days Inventory
- R&D Expenses/Sales
Not the Report you are looking for? Click here for more browsing options.
|
|
|
|
|
